For patients with locoregional advanced melanoma that can be treated with complete resection, adjuvant—and more recently neoadjuvant—with targeted therapy—BRAF and MEK inhibitors—and immunotherapy—anti-PD-1-based therapies—offer opportunities to reduce the risk of relapse and distant metastases. Here, BRAF is linked to melanoma.